Combination of new drug, CB-839, with everolimus stops advanced kidney tumors growing

November 29, 2016

Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it is used in combination with another anti-cancer drug, everolimus.

Dr Funda Meric-Bernstam told the 28th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany, today (Wednesday) that out of 15 patients with clear cell and papillary renal cell cancer who had been given the new drug CB-839 together with everolimus in a phase I clinical trial and for whom data were available to analyse, 93% had their tumour controlled by the regimen: the tumour shrank by more than 30% in one patient (called a partial response), was stable in 13 other patients (stable disease), and grew by more than 20% in the last patient (called progressive disease).

Clear cell is the most common form of kidney cancer, accounting for 75% of cases, and in this study all the patients with this form of the disease (12) had their disease controlled. Papillary renal cell cancer is the next most common form of the disease and accounts for 10% of cases.

CB-839 targets glutaminase, an enzyme involved in the conversion of glutamine to glutamate, which is an important nutrient for cancer cells - without it they die. Dr Meric-Bernstam, who is chair of the Department of Investigational Cancer Therapeutics and Medical Director of the Institute of Personalized Cancer Therapy at the University of Texas MD Anderson Cancer Centre (USA), said: "Glutaminase is a very interesting target and previous work in the lab has shown that CB-839 is effective at inhibiting it in renal cell cancers and that it enhances the anti-tumour efficacy of everolimus.

"To date, tumours in 93% of patients with clear cell and papillary renal cell cancers have had tumour control from the regimen, with a median [average] time without their cancer growing of 8.5 months. For more than half of these patients their time on this treatment has been longer than the time they remained on their prior treatment, which is considered to be a good sign."

The median number of previous treatments the patients had received was two, some of which included inhibitors of the mTOR cell signalling pathways, and checkpoint inhibitors that reactivate the body's immune system to attack the cancer. All had advanced or metastatic disease (cancer that has started to spread to other parts of the body). They were given CB-839 in oral doses that ranged from 400-800 mg twice a day in combination with a fixed oral dose of everolimus at 10 mg once a day. The patients tolerated the treatment well, with most adverse side effects being no more severe than was consistent with everolimus and advanced cancer.

"These results suggest that CB-839 is a very tolerable drug with significant potential in combination therapy for kidney cancer patients," said Dr Meric-Bernstam.

The researchers continue to enrol and treat patients in this trial, and they plan to evaluate CB-839 in combination with everolimus in a randomised controlled trial in the future. "In the current trial, we are also assessing the efficacy of CB-839 in kidney cancer in combination with another drug, cabozantinib. In another trial, we are evaluating the efficacy of CB-839 in combination with immunotherapy in kidney cancer, lung cancer and melanoma patients," she concluded.

Chair of the scientific committee for the Symposium, Professor Jean Charles Soria from the Institut Gustave Roussy (France), commented: "Compounds able to modulate cancer metabolism represent a new and innovative area for cancer drug development."
-end-
[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].

ECCO-the European CanCer Organisation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.